Hints and tips:
Related Special Reports
...Shares in GSK have fallen 5 per cent in the past five years, while many of its European rivals including Novo Nordisk, AstraZeneca and Novartis have soared....
...After the latter was bought by Swiss pharmaceutical group Roche in 2009, he rose through the ranks, becoming Genentech’s chief executive in 2017 and Roche’s head of pharma two years later....
...The pharmaceutical industry is close to agreeing a deal with the UK government over drug pricing, according to the chief financial officer of Swiss drugmaker Novartis....
...The crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the...
...Pharma companies, while talking up pipelines, are turning to deals to boost their growth outlook....
...Where doubts creep in is how Novartis will replace lost sales from 2027....
...Novartis would pay $37.5mn upfront with an additional $1.2bn in performance-based incentives....
...The results focus on the remaining business, focused on innovative drugs, after Novartis spun out its generics division Sandoz this month....
...GSK, the British pharma group, has struck a $1.4bn deal to acquire Anglo-American biotech Aiolos Bio, which makes respiratory medicines....
...He added that the underlying operative problems in the pharma and crop science businesses needed to be addressed without undue job cuts....
...The head of pharma group Novartis has warned that the US government’s reform of drug pricing risks damaging public health as drugmakers have already begun to cut investment in pills for the elderly....
...pharmaceutical companies are gathered in San Francisco for an annual industry conference this week, with GSK rivals Johnson & Johnson striking a $2bn deal to acquire an oncology biotech, and Merck and Novartis...
...The company also faces the expiration of key patents in its pharma division and last year aborted a late-stage trial of its most hopeful new drugs....
...focused Novartis”....
The Swiss pharma group needs to settle investor jitters with its latest acquisition
...Chief executive Bill Anderson, who joined last year after heading the pharma unit of Swiss rival Roche, said the decision “was not taken lightly” and had “considered investor input.”...
...Novartis recently said it would spin off its generic drugmaking business Sandoz....
...Shares in Novartis were up just over 3 per cent in early trading on Tuesday, but have languished this year....
...The Indianapolis-based pharma group has become the second major drugmaker after Swiss company Novartis to invest in radioligand therapy, which involves molecules delivering radiation at close range to cancerous...
...This raises funds for Schott AG’s green transition and gives Schott Pharma a chance to tap the capital markets if opportunities arise. The size of the offer is undecided....
...Manns said asundexian was the most promising drug in Bayer’s pharma pipeline. “Without it, the pharma unit is left without sustainable growth.”...
...The new chief executive, who has been in the job since the summer and previously ran Roche’s pharma division, disagreed that Bayer’s pharma unit was too small to keep up with larger rivals....
...Last month he blasted Bayer’s performance as “unacceptable” and stressed that “all options” were on the table, including splitting the pharma unit from the crop science division....
...index (PMI) data Japan: Chain Stores Association March supermarket sales UK: ONS March public sector finances and Kantar grocery market share data US: new home sales Results: Akzo Nobel Q1, Alliance Pharma...
...Monday’s acquisition by Novartis of Seattle-based biotech firm Chinook Therapeutics for up to $3.5bn is a case in point....
International Edition